CALC Stock Summary and Trading Ideas (Calcimedica | NASDAQ:CALC)

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Calcimedica trades on the NASDAQ stock market under the symbol CALC.

As of January 23, 2026, CALC stock price declined to $5.26 with 32,131 million shares trading.

CALC has a beta of 0.44, meaning it tends to be less sensitive to market movements. CALC has a correlation of 0.01 to the broad based SPY ETF.

CALC has a market cap of $75.74 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that CALC belongs to (by Net Assets): VTI, VXF.

CALC has outperformed the market in the last year with a return of +82.0%, while the SPY ETF gained +14.2%. In the last 3 month period, CALC beat the market returning +71.3%, while SPY returned +2.9%. However, in the most recent 2 weeks CALC has underperformed the stock market by returning -10.1%, while SPY returned -0.7%.

CALC support price is $4.91 and resistance is $5.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CALC shares will trade within this expected range on the day.